JENNA BAKER, PHD
Co-Founder & CEO
A broadly trained biologist whose research has spanned multiple disciplines, Jenna brings more than 20 years of life science experience in the academic, private, and government sectors to Gypsy Bay Genomics. By combining her background in computational and functional genomics with her leadership experience, she is helping GBG translate clinically relevant genomic signatures into advances in personalized clinical care.
Joe brings over 25 years of global healthcare experience in oncology, infectious disease, and respiratory therapeutic areas. He led the introduction for Merck of the first HPV vaccine, Gardasil, and was responsible for the formation of numerous global research, commercial, & manufacturing partnerships. He is recognized for his many successes commercializing technologies and building new product markets.
Senior Business Advisor
David is an seasoned healthcare CEO and Combat Veteran with over 20 years of experience commercializing diagnostics. He has built and scaled multiple healthcare companies that resulted in successful exits to strategic buyers. He was the CEO at Armune BioScience, which sold to Exact Sciences [EXAS] in Dec. 2017, as well as the US President at Phadia US/AB, which sold to Thermo Fisher Scientific [TMO] Sept. 2011).
Lynn has led the National Cervical Cancer Coalition, advocating for cervical health, vaccination, and HPV testing, as well as its parent organization, the American Sexual Health Association, as President and CEO since June 2006. She works closely with colleague organizations, from the American Sexual Transmitted Diseases Association, the National Coalition of STD Directors, and the Centers for Disease Control and Prevention.